David A. Flockhart

School of Medicine, Medicine, Clinical Pharmacology

• Home
• Expert Overview
• Profile
• Publications
• Grants
• Patents
• Similar Experts
• Journals
• Trends
• Institutional Network
• Coauthor Network
• Research Network
• Curriculum Vitae

David A. Flockhart

• School of Medicine
  School of Medicine
  
  Medicine
  
  Clinical Pharmacology
  
  

  Current Appointments:

  Harry and Edith Gladstein Professor of Cancer Epidemiology and Genetics

  
  
  

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.

  Select All    |   Export

• 1.

  2013

  Fen Jiang; Zeruesenay Desta; Ji-Hong Shon; Chang-Woo Yeo; Ho-Sook Kim; Kwang-Hyeon Liu; Soo-Kyung Bae; Sang-Seop Lee; David A. Flockhart; Jae-Gook Shin

  Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: Exploration of a novel CYP2B6 phenotyping index

  British Journal of Clinical Pharmacology. 2013;75(1):244-253.
  1

• 2.

  2013

  Heng-Yi Wu; Shreyas Karnik; Abhinita Subhadarshini; Zhiping Wang; Santosh Philips; Xu Han; Chienwei Chiang; Lei Liu; Malaz Boustani; Luis M. Rocha; et al.

  An integrated pharmacokinetics ontology and corpus for text mining

  BMC Bioinformatics. 2013;14(1).
  0

• 3.

  2013

  Rolf P. Kreutz; Perry Nystrom; Yvonne Kreutz; Jia Miao; Richard Kovacs; Zeruesenay Desta; David A. Flockhart; Yan Jin

  Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin

  Platelets. 2013;24(2):145-150.
  0

• 4.

  2013

  David L. Thacker; Anil Modak; David A. Flockhart; Zeruesenay Desta

  Is (+)-[¹³C]-pantoprazole better than (±)-[ ¹³C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?

  Journal of Breath Research. 2013;7(1).
  0

• 5.

  2013

  Rolf P Kreutz; David A Flockhart

  Amlodipine - Not a significant contributor to clopidogrel non-response?

  Heart. 2013;99(7):437-439.
  0

• 6.

  2013

  Rolf P. Kreutz; Janelle Owens; Jeffrey A. Breall; Deshun Lu; Elisabeth Von Der Lohe; Islam Bolad; Anjan Sinha; David A. Flockhart

  C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting

  Blood Coagulation and Fibrinolysis. 2013;24(3):321-326.
  0

• 7.

  2012

  Aditya Bardia; Erin T. Arieas; Zhe Zhang; Andrew Defilippis; Karineh Tarpinian; Stacie Jeter; Anne Nguyen; N. Lynn Henry; David A. Flockhart; Daniel F. Hayes; et al.

  Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer

  Breast Cancer Research and Treatment. 2012;131(3):907-914.
  3

• 8.

  2012

  Wenjie Jessie Lu; Zeruesenay Desta; David A. Flockhart

  Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer

  Breast Cancer Research and Treatment. 2012;131(2):473-481.
  8

• 9.

  2012

  Santosh Philips; Alexandra Richter; Steffi Oesterreich; James M. Rae; David A. Flockhart; Narayanan B. Perumal; Todd C. Skaar

  Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene

  Hormones and Cancer. 2012;3(1-2):37-43.
  1

• 10.

  2012

  V. Michaud; E. Ogburn; N. Thong; A.O. Aregbe; T.C. Quigg; D.A. Flockhart; Z. Desta

  Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers

  Clinical Pharmacology and Therapeutics. 2012;91(3):475-482.
  3

• 11.

  2012

  Kazuma Kiyotani; Taisei Mushiroda; Tatsuhiko Tsunoda; Takashi Morizono; Naoya Hosono; Michiaki Kubo; Yusuke Tanigawara; Chiyo K. Imamura; David A. Flockhart; Fuminori Aki; et al.

  A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese

  Human Molecular Genetics. 2012;21(7):1665-1672.
  10

• 12.

  2012

  S. Hennessy; D.A. Flockhart

  The need for translational research on drug-drug interactions

  Clinical Pharmacology and Therapeutics. 2012;91(5):771-773.
  2

• 13.

  2012

  William G. Newman; Dave Flockhart

  Breast cancer pharmacogenomics: Where we are going

  Pharmacogenomics. 2012;13(6):629-631.
  0

• 14.

  2012

  Wenjie Jessie Lu; Cong Xu; Zifan Pei; Abdelrahman S. Mayhoub; Mark Cushman; David A. Flockhart

  The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

  Breast Cancer Research and Treatment. 2012;133(1):99-109.
  0

• 15.

  2012

  N. Lynn Henry; Faouzi Azzouz; Zereunesay Desta; Lang Li; Anne T. Nguyen; Suzanne Lemler; Jill Hayden; Karineh Tarpinian; Elizabeth Yakim; David A. Flockhart; et al.

  Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer

  Journal of Clinical Oncology. 2012;30(9):936-942.
  12

• 16.

  2012

  R.J. Hartmaier; A.S. Richter; R.M. Gillihan; J.Z. Sallit; S.E. Mcguire; J. Wang; A.V. Lee; C.K. Osborne; B.W. O'Malley; P.H. Brown; et al.

  A snp in steroid receptor coactivator-1 disrupts a gsk3β phosphorylation site and is associated with altered tamoxifen response in bone

  Molecular Endocrinology. 2012;26(2):220-227.
  2

• 17.

  2012

  Rolf P. Kreutz; Perry Nystrom; Yvonne Kreutz; Jia Miao; Zeruesenay Desta; Jeffrey A. Breall; Lang Li; ChienWei Chiang; Richard Kovacs; David A. Flockhart; et al.

  Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response

  Clinical Pharmacology: Advances and Applications. 2012;4(1):13-20.
  2

• 18.

  2012

  Anuradha Ramamoorthy; Lang Li; Andrea Gaedigk; L. DiAnne Bradford; Eric A. Benson; David A. Flockhart; Todd C. Skaar

  In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression

  Drug Metabolism and Disposition. 2012;40(4):726-733.
  5

• 19.

  2012

  Veronique Michaud; Tamara Bar-Magen; Jacques Turgeon; David Flockhart; Zeruesenay Desta; Mark A. Wainberg

  The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition

  Pharmacological Reviews. 2012;64(3):803-833.
  1

• 20.

  2012

  Wenjie Jessie Lu; Nancy Thong; David A. Flockhart

  Reduced methadone clearance during aromatase inhibition

  Journal of Clinical Psychopharmacology. 2012;32(4):511-517.
  0

• 21.

  2012

  Rolf P. Kreutz; Jeffrey A. Breall; Yvonne Kreutz; Janelle Owens; Deshun Lu; Islam Bolad; Elisabeth Von Der Lohe; Anjan Sinha; David A. Flockhart

  Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response

  Thrombosis Research. 2012;130(2):198-202.
  0

• 22.

  2012

  Lawrence J. Cohen; David A. Sclar; Larry Culpepper; David A. Flockhart; Robert M. A. Hirschfeld; Michael E. Thase; Chad M. VanDenBerg

  Discussion: A fresh look at monoamine oxidase inhibitors for depression

  Journal of Clinical Psychiatry. 2012;73(SUPPL. 1):42-45.
  1

• 23.

  2012

  David A. Flockhart

  Dietary restrictions and drug interactions with monoamine oxidase inhibitors: An update

  Journal of Clinical Psychiatry. 2012;73(SUPPL. 1):17-24.
  1

• 24.

  2012

  Y Ji; J M Biernacka; S Hebbring; Y Chai; G D Jenkins; A Batzler; K A Snyder; M S Drews; Z Desta; D Flockhart; et al.

  Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics

  Pharmacogenomics Journal. 2012.
  1

• 25.

  2012

  Yusuke Nakamura; Mark J. Ratain; Nancy J. Cox; Howard L. McLeod; Deanna L. Kroetz; David A. Flockhart

  Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial

  Journal of the National Cancer Institute. 2012;104(16):1264.
  8

• 26.

  2012

  Santosh Philips; James M. Rae; Steffi Oesterreich; Daniel F. Hayes; Vered Stearns; N. Lynn Henry; Anna M. Storniolo; David A. Flockhart; Todd C. Skaar

  Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes

  Frontiers in Pharmacology. 2012;3 MAR.
  0

• 27.

  2012

  James E. Tisdale; Brian R. Overholser; Heather A. Wroblewski; Kevin M. Sowinski; Kwadwo Amankwa; Steven Borzak; Joanna R. Kingery; Rita Coram; Douglas P. Zipes; David A. Flockhart; et al.

  Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction

  Journal of Clinical Pharmacology. 2012;52(9):1296-1305.
  0

• 28.

  2012

  Jon D. Duke; Xu Han; Zhiping Wang; Abhinita Subhadarshini; Shreyas D. Karnik; Xiaochun Li; Stephen D. Hall; Yan Jin; J. Thomas Callaghan; Marcus J. Overhage; et al.

  Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions

  PLoS Computational Biology. 2012;8(8).
  1

• 29.

  2012

  Kye-Min Kim; Michael D. Murray; Wanzhu Tu; Jason Robarge; Yan Ding; D. Craig Brater; David A. Flockhart

  Pharmacogenetics and healthcare outcomes in patients with chronic heart failure

  European Journal of Clinical Pharmacology. 2012;68(11):1483-1491.
  0

• 30.

  2012

  Lauren Nicole Bell; Anne Thi Phuong Nguyen; Lang Li; Zeruesenay Desta; N. Lynn Henry; Daniel F. Hayes; Antonio C. Wolff; Vered Stearns; Anna Maria Storniolo; David A. Flockhart

  Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole

  Journal of Clinical Pharmacology. 2012;52(12):1852-1860.
  0

• 31.

  2011

  Landry K. Kamdem; David A. Flockhart; Zeruesenay Desta

  In vitro cytochrome P450-mediated metabolism of exemestane

  Drug Metabolism and Disposition. 2011;39(1):98-105.
  9

• 32.

  2011

  K.L. Rand; J.L. Otte; D. Flockhart; D. Hayes; A.M. Storniolo; V. Stearns; N.L. Henry; A. Nguyen; S. Lemler; J. Hayden; et al.

  Modeling hot flushes and quality of life in breast cancer survivors

  Climacteric. 2011;14(1):171-180.
  12

• 33.

  2011

  Rolf P. Kreutz; Mouhamad Alloosh; Khaled Mansour; Zachary Neeb; Yvonne Kreutz; David A. Flockhart; Michael Sturek

  Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity

  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2011;4:99-105.
  8

• 34.

  2011

  Changyu Shen; Yiwen Huang; Yunlong Liu; Guohua Wang; Yuming Zhao; Zhiping Wang; Mingxiang Teng; Yadong Wang; David A. Flockhart; Todd C. Skaar; et al.

  A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer

  BMC Systems Biology. 2011;5.
  8

• 35.

  2011

  David M. Haas; Beverly Gallauresi; Kristine Shields; Deborah Zeitlin; Shannon M. Clark; Mary F. Hebert; Zhaoxia Ren; Srikanth C. Nallani; Eric M. Meslin; Karen B. Feibus; et al.

  Pharmacotherapy and pregnancy: Highlights from the third international conference for individualized pharmacotherapy in pregnancy

  Clinical and Translational Science. 2011;4(3):204-209.
  1

• 36.

  2011

  Véronique Michaud; Jacques Turgeon; David Flockhart; Mark A. Wainberg

  Role of pharmacogenetics in the metabolism and transport of antiretroviral drugs

  Virologie. 2011;15(3):157-174.
  0

• 37.

  2011

  William J. Irvin Jr.; Christine M. Walko; Karen E. Weck; Joseph G. Ibrahim; Wing K. Chiu; E. Claire Dees; Susan G. Moore; Oludamilola A. Olajide; Mark L. Graham; Sean T. Canale; et al.

  Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study

  Journal of Clinical Oncology. 2011;29(24):3232-3239.
  35

• 38.

  2011

  Wenjie J Lu; Weidong Zhou; Yvonne Kreutz; David A Flockhart

  Methadone adverse reaction presenting with large increase in plasma methadone binding: A case series

  Journal of Medical Case Reports. 2011;5.
  1

• 39.

  2011

  David L. Thacker; Anil Modak; Phuong D. Nguyen; David A. Flockhart; Zeruesenay Desta

  Stereoselective pharmacokinetics of stable isotope (+/-)-[ ¹³C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity

  Chirality. 2011;23(10):904-909.
  3

• 40.

  2011

  Wenjie Jessie Lu; Valentina Ferlito; Cong Xu; David Alastair Flockhart; Salvatore Caccamese

  Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms

  Chirality. 2011;23(10):891-896.
  4

• 41.

  2011

  Z. Desta; Y. Kreutz; A.T. Nguyen; L. Li; T. Skaar; L.K. Kamdem; N.L. Henry; D.F. Hayes; A.M. Storniolo; V. Stearns; et al.

  Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age

  Clinical Pharmacology and Therapeutics. 2011;90(5):693-700.
  9

• 42.

  2011

  Matthew P. Goetz; Daniel J. Schaid; D. Lawrence Wickerham; Stephanie Safgren; Taisei Mushiroda; Michiaki Kubo; Anthony Batzler; Joseph P. Costantino; Victor G. Vogel; Soonmyung Paik; et al.

  Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: Results from the NSABP P1 and P2 clinical trials

  Clinical Cancer Research. 2011;17(21):6944-6951.
  12

• 43.

  2011

  Alette M. Wessels; David A. Flockhart; Janet S. Carpenter; Milan Radovich; Lang Li; Kathy D. Miller; George W. Sledge; Anna M. Storniolo; Julie L. Otte; Suzanne M. Lemler; et al.

  Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving Doxorubicin and cyclophosphamide

  Breast Journal. 2011;17(5):536-538.
  0

• 44.

  2011

  David Euhus; Dawei Bu; Xian-Jin Xie; Venetia Sarode; Raheela Ashfaq; Kelly Hunt; Weiya Xia; Joyce O'Shaughnessy; Michael Grant; Banu Arun; et al.

  Tamoxifen downregulates Ets oncogene family members ETV4 and ETV5 in benign breast tissue: Implications for durable risk reduction

  Cancer Prevention Research. 2011;4(11):1852-1862.
  1

• 45.

  2011

  Marcelo F. Montenegro; Carla S. Ceron; Maria C.O. Salgado; Zeruesenay Desta; David A. Flockhart; Jose E. Tanus-Santos

  Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis

  Journal of Cardiovascular Pharmacology. 2011;58(6):647-653.
  2

• 46.

  2010

  S. Borges; Z. Desta; Y. Jin; A. Faouzi; J.D. Robarge; S. Philip; A. Nguyen; V. Stearns; D. Hayes; J.M. Rae; et al.

  Erratum: Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients (Journal of Clinical Pharmacology (2010) 50: 4 (450-458) DOI: 10.1177/0091270009359182)

  Journal of Clinical Pharmacology. 2010;50(6):725.
  0

• 47.

  2010

  Anuradha Ramamoorthy; David A. Flockhart; Naoya Hosono; Michiaki Kubo; Yusuke Nakamura; Todd C. Skaar

  Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays

  Pharmacogenetics and Genomics. 2010;20(7):451-454.
  7

• 48.

  2010

  Wenjie Jessie Lu; Robert Bies; Landry K. Kamden; Zeruesenay Desta; David A. Flockhart

  Methadone: A substrate and mechanism-based inhibitor of CYP19 (aromatase)

  Drug Metabolism and Disposition. 2010;38(8):1308-1313.
  12

• 49.

  2010

  N.L. Henry; D. Pchejetski; R. A'Hern; A.T. Nguyen; P. Charles; J. Waxman; L. Li; A.M. Storniolo; D.F. Hayes; D.A. Flockhart; et al.

  Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study

  British Journal of Cancer. 2010;103(3):291-296.
  10

• 50.

  2010

  Rolf P. Kreutz; Eric J. Stanek; Ronald Aubert; Jianying Yao; Jeffrey A. Breall; Zeruesenay Desta; Todd C. Skaar; J. Russell Teagarden; Felix W. Frueh; Robert S. Epstein; et al.

  Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: The clopidogrel Medco outcomes study

  Pharmacotherapy. 2010;30(8):787-796.
  58

• 51.

  2010

  Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; et al.

  Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

  Journal of clinical pharmacology. 2010;50(4):450-458.
  30

• 52.

  2010

  D.F. Hayes; T.C. Skaar; J.M. Rae; N.L. Henry; A.T. Nguyen; V. Stearns; L. Li; S. Philips; Z. Desta; D.A. Flockhart

  Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: Revised and updated results

  Clinical Pharmacology and Therapeutics. 2010;88(5):626-629.
  2

• 53.

  2010

  James N. Ingle; Daniel J. Schaid; Paul E. Goss; Mohan Liu; Taisei Mushiroda; Judy-Anne W. Chapman; Michiaki Kubo; Gregory D. Jenkins; Anthony Batzler; Lois Shepherd; et al.

  Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors

  Journal of Clinical Oncology. 2010;28(31):4674-4682.
  49

• 54.

  2010

  Landry K. Kamdem; Yong Liu; Vered Stearns; Susan A. Kadlubar; Jacqueline Ramirez; Stacie Jeter; Karineh Shahverdi; Bryan A. Ward; Evan Ogburn; Mark J. Ratain; et al.

  In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole

  British Journal of Clinical Pharmacology. 2010;70(6):854-869.
  8

• 55.

  2010

  Andrew N. Freedman; Leah B. Sansbury; William D. Figg; Arnold L. Potosky; Sheila R. Weiss Smith; Muin J. Khoury; Stefanie A. Nelson; Richard M. Weinshilboum; Mark J. Ratain; Howard L. McLeod; et al.

  Cancer pharmacogenomics and pharmacoepidemiology: Setting a research agenda to accelerate translation

  Journal of the National Cancer Institute. 2010;102(22):1698-1705.
  19

• 56.

  2010

  N.L. Henry; A. Nguyen; F. Azzouz; L. Li; J. Robarge; S. Philips; D. Cao; T.C. Skaar; J.M. Rae; A.M. Storniolo; et al.

  Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy

  British Journal of Cancer. 2010;102(2):294-300.
  7

• 57.

  2010

  Kazuma Kiyotani; Taisei Mushiroda; Chiyo K. Imamura; Naoya Hosono; Tatsuhiko Tsunoda; Michiaki Kubo; Yusuke Tanigawara; David A. Flockhart; Zeruesenay Desta; Todd C. Skaar; et al.

  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

  Journal of Clinical Oncology. 2010;28(8):1287-1293.
  75

• 58.

  2010

  James N. Ingle; Aman U. Buzdar; Daniel J. Schaid; Matthew P. Goetz; Anthony Batzler; Mark E. Robson; Donald W. Northfelt; Janet E. Olson; Edith A. Perez; Zeruesenay Desta; et al.

  Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer

  Cancer Research. 2010;70(8):3278-3286.
  15

• 59.

  2010

  Lang Li; Silvana Borges; Robarge D. Jason; Changyu Shen; Zeruesenay Desta; David Flockhart

  A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypes

  Cancer Informatics. 2010;9:93-103.
  1

• 60.

  2009

  David M Haas; Jamie L Renbarger; Scott Denne; Mahmoud S Ahmed; Thomas Easterling; Karen Feibus; Eric M Meslin; Gideon Koren; Anne Zajicek; Wayne R Snodgrass; et al.

  Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy.

  Clinical and translational science. 2009;2(1):11-14.
  2

• 61.

  2009

  David M. Haas; Mary F. Hebert; Offie P. Soldin; David A. Flockhart; Parvaz Madadi; James J. Nocon; Christina D. Chambers; Gary D. Hankins; Shannon Clark; Katherine L. Wisner; et al.

  Pharmacotherapy and pregnancy: Highlights from the second international conference for individualized pharmacotherapy in pregnancy

  Clinical and Translational Science. 2009;2(6):439-443.
  7

• 62.

  2009

  Michaela J. Higgins; James M. Rae; David A. Flockhart; Daniel F. Hayes; Vered Stearns

  Pharmacogenetics of tamoxifen: Who should undergo CYP2D6 genetic testing?

  JNCCN Journal of the National Comprehensive Cancer Network. 2009;7(2):203-213.
  32

• 63.

  2009

  Zeruesenay Desta; Anil Modak; Phuong D. Nguyen; Suzanne M. Lemler; Yasuhisa Kurogi; Lang Li; David A. Flockhart

  Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [ ¹³C]pantoprazole breath test

  Journal of Pharmacology and Experimental Therapeutics. 2009;329(1):297-305.
  13

• 64.

  2009

  Marcelo F. Montenegro; Lisandra R. Pessa; Valéria A. Gomes; Zeruesenay Desta; David A. Flockhart; Jose E. Tanus-Santos

  Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed

  Basic and Clinical Pharmacology and Toxicology. 2009;104(5):400-407.
  9

• 65.

  2009

  Adedayo A. Onitilo; Catherine A. McCarty; Russell A. Wilke; Ingrid Glurich; Jessica M. Engel; David A. Flockhart; Anne Nguyen; Lang Li; Deming Mi; Todd C. Skaar; et al.

  Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy

  Breast Cancer Research and Treatment. 2009;115(3):643-650.
  14

• 66.

  2009

  D.A. Flockhart; T. Skaar; D.S. Berlin; T.E. Klein; A.T. Nguyen

  Clinically available pharmacogenomics tests

  Clinical Pharmacology and Therapeutics. 2009;86(1):109-113.
  36

• 67.

  2009

  Zeruesenay Desta; Anne Nguyen; David Flockhart; Todd Skaar; Rebecca Fletcher; Richard Weinshilboum; Dorit S. Berlin; Teri E. Klein; Russ B. Altman

  Antiestrogen pathway (aromatase inhibitor)

  Pharmacogenetics and Genomics. 2009;19(7):554-555.
  2

• 68.

  2009

  J.M. Rae; M.J. Sikora; N.L. Henry; L. Li; S. Kim; S. Oesterreich; T.C. Skaar; A.T. Nguyen; Z. Desta; A.M. Storniolo; et al.

  Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

  Pharmacogenomics Journal. 2009;9(4):258-264.
  40

• 69.

  2009

  Julie L. Otte; David Flockhart; Daniel Hayes; Anna Maria Storniolo; Vered Stearns; Bryan Schneider; N. Lynn Henry; Faouzi Azzouz; Anne Nguyen; Suzanne Lemler; et al.

  Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy

  Menopause. 2009;16(4):653-659.
  10

• 70.

  2009

  Seongwook Jeong; Margaret M. Woo; David A. Flockhart; Zeruesenay Desta

  Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol- bisbenzonitrile in vitro

  Cancer Chemotherapy and Pharmacology. 2009;64(5):867-875.
  12

• 71.

  2009

  Million Arefayene; Santosh Philips; Donghua Cao; Sudharani Mamidipalli; Zeruesenay Desta; David A. Flockhart; David S. Wilkes; Todd C. Skaar

  Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity

  Pharmacogenetics and Genomics. 2009;19(6):464-476.
  13

• 72.

  2009

  Bryan P. Schneider; Milan Radovich; David A. Flockhart; Janet S. Carpenter; Lang Li; Jason D. Robarge; Anna M. Storniolo; Bradley A. Hancock; Todd C. Skaar; George W. Sledge

  Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes

  Breast Cancer Research and Treatment. 2009;116(3):543-549.
  3

• 73.

  2009

  N. Lynn Henry; James M. Rae; Lang Li; Faouzi Azzouz; Todd C. Skaar; Zereunesay Desta; Matthew J. Sikora; Santosh Philips; Anne T. Nguyen; Anna Maria Storniolo; et al.

  Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

  Breast Cancer Research and Treatment. 2009;117(3):571-575.
  36

• 74.

  2009

  Sheldon H. Preskorn; David Flockhart

  2010 guide to psychiatric drug interactions

  Primary Psychiatry. 2009;16(12):45-74.
  11

• 75.

  2008

  David A. Flockhart; Dennis O'Kane; Marc S. Williams; Michael S. Watson

  Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

  Genetics in Medicine. 2008;10(2):139-150.
  103

• 76.

  2008

  N.I. Ntukidem; A.T. Nguyen; V. Stearns; M. Rehman; A. Schott; T. Skaar; Y. Jin; P. Blanche; L. Li; S. Lemler; et al.

  Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen

  Clinical Pharmacology and Therapeutics. 2008;83(5):702-710.
  26

• 77.

  2008

  Daniel F. Hayes; Vered Stearns; James Rae; David Flockhart

  A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

  Journal of the National Cancer Institute. 2008;100(9):610-613.
  30

• 78.

  2008

  Scott T. Weiss; Howard L. McLeod; David A. Flockhart; M. Eileen Dolan; Neal L. Benowitz; Julie A. Johnson; Mark J. Ratain; Kathleen M. Giacomini

  Creating and evaluating genetic tests predictive of drug response

  Nature Reviews Drug Discovery. 2008;7(7):568-574.
  25

• 79.

  2008

  Bryan P. Schneider; Milan Radovich; George W. Sledge; Jason D. Robarge; Lang Li; Anna M. Storniolo; Suzanne Lemler; Anne T. Nguyen; Bradley A. Hancock; Michael Stout; et al.

  Association of polymorphisms of angiogenesis genes with breast cancer

  Breast Cancer Research and Treatment. 2008;111(1):157-163.
  47

• 80.

  2008

  N. Lynn Henry; Jon T. Giles; Dennis Ang; Monika Mohan; Dina Dadabhoy; Jason Robarge; Jill Hayden; Suzanne Lemler; Karineh Shahverdi; Penny Powers; et al.

  Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors

  Breast Cancer Research and Treatment. 2008;111(2):365-372.
  43

• 81.

  2008

  D.A. Flockhart; D.R. Abernethy

  Finding the right research question: Quality science depends on quality careers

  Clinical Pharmacology and Therapeutics. 2008;84(3):427-429.
  2

• 82.

  2008

  Zeruesenay Desta; David A. Flockhart

  In reply

  Journal of Clinical Oncology. 2008;26(10):1765-1766.
  1

• 83.

  2008

  David Flockhart

  CYP2D6 genotyping and the pharmacogenetics of tamoxifen

  Clinical Advances in Hematology and Oncology. 2008;6(7):493-494.
  6

• 84.

  2008

  Daniel F. Hayes; Vered Stearns; James Rae; David Flockhart

  Response: Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis

  Journal of the National Cancer Institute. 2008;100(18):1333-1334.
  0

• 85.

  2008

  Matthew P. Goetz; Vera J. Suman; Fergus J. Couch; Matthew M. Ames; James M. Rae; Mark G. Erlander; Xiao-Jun Ma; Dennis C. Sgroi; Carol A. Reynolds; Wilma L. Lingle; et al.

  Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: Combining inherited and tumor gene markers for prediction of tamoxifen resistance

  Clinical Cancer Research. 2008;14(18):5864-5868.
  16

• 86.

  2008

  Bryan P. Schneider; Molin Wang; Milan Radovich; George W. Sledge; Sunil Badve; Ann Thor; David A. Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; et al.

  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100

  Journal of Clinical Oncology. 2008;26(28):4672-4678.
  292

• 87.

  2008

  N. Lynn Henry; Vered Stearns; David A. Flockhart; Daniel F. Hayes; Michelle Riba

  Drug interactions and pharmacogenomics in the treatment of breast cancer and depression

  American Journal of Psychiatry. 2008;165(10):1251-1255.
  34

• 88.

  2008

  Nita A. Limdi; T. Mark Beasley; Michael R. Crowley; Joyce A. Goldstein; Mark J. Rieder; David A. Flockhart; Donna K. Arnett; Ronald T. Acton; Nianjun Liu

  VKORC1 polymorphims, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans

  Pharmacogenomics. 2008;9(10):1445-1458.
  45

• 89.

  2008

  James E. Tisdale; Brian R. Overholser; Kevin M. Sowinski; Heather A. Wroblewski; Kwadwo Amankwa; Steven Borzak; Joanna R. Kingery; Rita Coram; Douglas P. Zipes; David A. Flockhart; et al.

  Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction

  Pharmacotherapy. 2008;28(12):1461-1470.
  2

• 90.

  2008

  Lang Li; Menggang Yu; Robarge D. Jason; Changyu Shen; Faouzi Azzouz; Howard L. McLeod; Silvana Borges-Gonzales; Anne Nguyen; Todd Skaar; Zeruesenay Desta; et al.

  A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes

  Journal of Biopharmaceutical Statistics. 2008;18(6):1150-1177.
  1

• 91.

  2008

  Yan Jin; Daniel F. Hayes; Lang Li; Jason D. Robarge; Todd C. Skaar; Santosh Philips; Anne Nguyen; Anne Schott; Jill Hayden; Suzanne Lemler; et al.

  Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy

  Journal of Clinical Oncology. 2008;26(36):5849-5854.
  21

• 92.

  2008

  David M. Haas; Jamie L. Renbarger; Eric M. Meslin; Katherine Drabiak; David Flockhart

  Patient attitudes toward genotyping in an urban women's health clinic

  Obstetrics and Gynecology. 2008;112(5):1023-1028.
  4

• 93.

  2007

  Jae-Gook Shin; Won-Ku Kang; Ji-Hong Shon; Million Arefayene; Young-Ran Yoon; Kyung-Ah Kim; Doo-Il Kim; Dong-Soo Kim; Kwang-Hyun Cho; Raymond L. Woosley; et al.

  Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects

  British Journal of Clinical Pharmacology. 2007;63(2):206-215.
  15

• 94.

  2007

  Sheldon H. Preskorn; David J. Greenblatt; David Flockhart; Yan Luo; Elke S. Perloff; Jerold S. Harmatz; Bryan Baker; Alisa Klick-Davis; Zereusenay Desta; Tal Burt

  Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers

  Journal of Clinical Psychopharmacology. 2007;27(1):28-34.
  40

• 95.

  2007

  Matthew P. Goetz; Stacey K. Knox; Vera J. Suman; James M. Rae; Stephanie L. Safgren; Matthew M. Ames; Daniel W. Visscher; Carol Reynolds; Fergus J. Couch; Wilma L. Lingle; et al.

  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

  Breast Cancer Research and Treatment. 2007;101(1):113-121.
  332

• 96.

  2007

  A. Nguyen; Z. Desta; D.A. Flockhart

  Enhancing race-based prescribing precision with pharmacogenomics

  Clinical Pharmacology and Therapeutics. 2007;81(3):323-325.
  5

• 97.

  2007

  K.M. Giacomini; C.M. Brett; R.B. Altman; N.L. Benowitz; M.E. Dolan; D.A. Flockhart; J.A. Johnson; D.F. Hayes; T. Klein; R.M. Krauss; et al.

  The Pharmacogenetics Research Network: From SNP discovery to clinical drug response

  Clinical Pharmacology and Therapeutics. 2007;81(3):328-345.
  99

• 98.

  2007

  J.D. Robarge; L. Li; Z. Desta; A. Nguyen; D.A. Flockhart

  The star-allele nomenclature: Retooling for translational genomics

  Clinical Pharmacology and Therapeutics. 2007;82(3):244-248.
  8

• 99.

  2007

  Lang Li; Menggang Yu; Raymond Chin; Aroonrut Lucksiri; David A. Flockhart; Stephen D. Hall

  Drug-drug interaction prediction: A Bayesian meta-analysis approach

  Statistics in Medicine. 2007;26(20):3700-3721.
  11

• 100.

  2007

  Lang Li; Siu Hui; Gene Pennello; Zeruesenay Desta; Skaar Todd; Anne Nguyen; David Flockhart

  Estimating a positive false discovery rate for variable selection in pharmacogenetic studies

  Journal of Biopharmaceutical Statistics. 2007;17(5):883-902.
  1

• 101.

  2007

  Holly M. Knoderer; Jason Robarge; David A. Flockhart

  Predicting asparaginase-associated pancreatitis

  Pediatric Blood and Cancer. 2007;49(5):634-639.
  23

• 102.

  2007

  Russell A. Wilke; Debbie W. Lin; Dan M. Roden; Paul B. Watkins; David Flockhart; Issam Zineh; Kathleen M. Giacomini; Ronald M. Krauss

  Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges

  Nature Reviews Drug Discovery. 2007;6(11):904-916.
  103

• 103.

  2007

  Zeruesenay Desta; David A. Flockhart

  Germline pharmacogenetics of tamoxifen response: Have we learned enough?

  Journal of Clinical Oncology. 2007;25(33):5147-5149.
  20

• 104.

  2007

  Janet S. Carpenter; David Flockhart

  Flash points

  Journal of Clinical Oncology. 2007;25(35):5546-5547.
  0

• 105.

  2007

  Russ B. Altman; Neal Benowitz; David Gurwitz; Jeantine Lunshol; Mary Relling; Jatinder Lamba; Eric Wieben; Sean Mooney; Kathleen Giacomini; Scott Weiss; et al.

  Genetic nondiscrimination legislation: A critical prerequisite for pharmacogenomics data sharing

  Pharmacogenomics. 2007;8(5):519.
  6

• 106.

  2007

  Zeruesenay Destra; Tanja Saussele; Bryan Ward; Julia Blievernicht; Lang Li; Kathrin Klein; David A. Flockhart; Ulricht M. Zanger

  Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro

  Pharmacogenomics. 2007;8(6):547-558.
  81

• 107.

  2006

  Dan M. Roden; Russ B. Altman; Neal L. Benowitz; David A. Flockhart; Kathleen M. Giacomini; Julie A. Johnson; Ronald M. Krauss; Howard L. McLeod; Mark J. Ratain; Mary V. Relling; et al.

  Pharmacogenomics: Challenges and opportunities

  Annals of Internal Medicine. 2006;145(10):749-757.
  106

• 108.

  2006

  Jae-Gook Shin; Kyung-Hoon Lee; Fabio Leonessa; Robert Clarke; David Alastair Flockhart

  The disposition of reduced haloperidol and HPP,⁺ metabolites of haloperidol, is not influenced by P-glycoprotein

  Journal of Korean Society for Clinical Pharmacology and Therapeutics. 2006;14(1):42-50.
  0

• 109.

  2006

  Matthew P. Goetz; James M. Rae; Stephanie L. Safgren; Matthew M. Ames; Daniel W. Visscher; Carol Reynolds; Fergus Couch; Wilma L. Lingle; David A. Flockhart; Zeruesenay Desta; et al.

  In reply [2]

  Journal of Clinical Oncology. 2006;24(22):3709.
  0

• 110.

  2006

  Bryan P. Schneider; Todd C. Skaar; George W. Sledge; Sunil Badve; Lang Li; David A. Flockhart

  Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes

  Breast Cancer Research and Treatment. 2006;96(3):209-215.
  19

• 111.

  2006

  Barbara J. Evans; David A. Flockhart

  The unfinished business of U.S. drug safety regulation

  Food and Drug Law Journal. 2006;61(1):45-63+i-ii.
  3

• 112.

  2006

  Sheldon H. Preskorn; David Flockhart

  2006 Guide to psychiatric drug interactions

  Primary Psychiatry. 2006;13(4):35-64.
  20

• 113.

  2006

  Silvana Borges; Zeruesenay Desta; Lang Li; Todd C. Skaar; Bryan A. Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D. Michele Nikoloff; Lin Wu; et al.

  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

  Clinical Pharmacology and Therapeutics. 2006;80(1):61-74.
  244

• 114.

  2006

  Chai Lim Young; Lang Li; Zeruesenay Desta; Qianqian Zhao; James M. Rae; David A. Flockhart; Todd C. Skaar

  Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

  Journal of Pharmacology and Experimental Therapeutics. 2006;318(2):503-512.
  62

• 115.

  2006

  Sheldon H. Preskorn; Silvana Borges; David Flockhart

  Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part I

  Journal of Psychiatric Practice. 2006;12(4):244-249.
  9

• 116.

  2006

  Sheldon H. Preskorn; Silvana Borges-Gonzalez; David Flockhart

  Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II

  Journal of Psychiatric Practice. 2006;12(5):312-316.
  5

• 117.

  2006

  Vered Stearns; Bryan Schneider; N. Lynn Henry; Daniel F. Hayes; David A. Flockhart

  Breast cancer treatment and ovarian failure: Risk factors and emerging genetic determinants

  Nature Reviews Cancer. 2006;6(11):886-893.
  28

• 118.

  2006

  Valéria C. Sandrim; Juan C. Yugar-Toledo; Zeruesenay Desta; David A. Flockhart; Heitor Moreno Jr.; Jose E. Tanus-Santos

  Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy

  Journal of Hypertension. 2006;24(12):2393-2397.
  33

• 119.

  2006

  Stephen Bernard; Kathleen A. Neville; Anne T. Nguyen; David A. Flockhart

  Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications

  Oncologist. 2006;11(2):126-135.
  83

• 120.

  2005

  Matthew P. Goetz; James M. Rae; Vera J. Suman; Stephanie L. Safgren; Matthew M. Ames; Daniel W. Visscher; Carol Reynolds; Fergus J. Couch; Wilma L. Lingle; David A. Flockhart; et al.

  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

  Journal of Clinical Oncology. 2005;23(36):9312-9318.
  429

• 121.

  2005

  James M Rae; Matthew P Goetz; Daniel F Hayes; James N Ingle; Lang Li; Anna Maria Storniolo; Vered Stearns; David A Flockhart

  CYP2D6 genotype and tamoxifen response.

  Breast cancer research : BCR. 2005;7(5):E6.
  11

• 122.

  2005

  Young Chai Lim; Zeruesenay Desta; David A. Flockhart; Todd C. Skaar

  Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

  Cancer Chemotherapy and Pharmacology. 2005;55(5):471-478.
  98

• 123.

  2005

  Herbert Ho; Amar Pinto; Stephen D. Hall; David A. Flockhart; Lang Li; Todd C. Skaar; Peter Cadman; Daniel T. O'Connor; Urban Wagner; Naomi S. Fineberg; et al.

  Association between the CYP3A5 genotype and blood pressure

  Hypertension. 2005;45(2):294-298.
  52

• 124.

  2005

  Yan Jin; Zeruesenay Desta; Vered Stearns; Bryan Ward; Herbert Ho; Kyung-Hoon Lee; Todd Skaar; Anna Maria Storniolo; Lang Li; Adjei Araba; et al.

  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

  Journal of the National Cancer Institute. 2005;97(1):30-39.
  484

• 125.

  2005

  Marc E. Lippman; Chris Benz; Arul Chinnaiyan; David Flockhart; Adrian Harris; Clifford Hudis; C. Kent Osborne; Michael F. Press; James Rae; George W. Sledge; et al.

  Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer - The Development and Validation of New Therapeutics'

  Breast Cancer Research and Treatment. 2005;90(1):1-3.
  2

• 126.

  2005

  Ingrid F. Metzger; Debora C. Souza-Costa; Aline S. Marroni; Sabrina Nagassaki; Zeruesenay Desta; David A. Flockhart; Jose Edwardo Tanus-Santos

  Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men

  Pharmacogenetics and Genomics. 2005;15(8):565-570.
  65

• 127.

  2005

  Tommy Andersson; David A. Flockhart; David B. Goldstein; Shiew-Mei Huang; Deanna L. Kroetz; Patrice M. Milos; Mark J. Ratain; Kenneth Thummel

  Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests

  Clinical Pharmacology and Therapeutics. 2005;78(6):559-581.
  72

• 128.

  2005

  Adegboyega Q. Adigun; Amar G. Pinto; David A. Flockhart; J. Christopher Gorski; Lang Li; Stephen D. Hall; Naga Chalasani

  Effect of cirrhosis and liver transplantation on the gender difference in QT interval

  American Journal of Cardiology. 2005;95(5):691-694.
  7

• 129.

  2005

  Olga Vitseva; David A. Flockhart; Yan Jin; Sonia Varghese; Jane E. Freedman

  The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates

  Journal of Pharmacology and Experimental Therapeutics. 2005;312(3):1144-1150.
  21

• 130.

  2004

  Barbara J. Evans; David A. Flockhart; Eric M. Meslin

  Creating incentives for genomic research to improve targeting of therapies

  Nature Medicine. 2004;10(12):1289-1291.
  11

• 131.

  2004

  Lang Li; Mehul Desai; Zeruesenay Desta; David Flockhart

  QT analysis: A complex answer to a 'simple' problem

  Statistics in Medicine. 2004;23(17):2625-2643.
  14

• 132.

  2004

  Anne T. Harvey; David Flockhart; J. Christopher Gorski; David J. Greenblatt; Michael Burke; Steve Werder; Sheldon H. Preskorn

  Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia

  Journal of Clinical Pharmacology. 2004;44(10):1173-1184.
  9

• 133.

  2004

  Bryan A. Ward; Alan Morocho; Abdullah Kandil; Raymond E. Galinsky; David A. Flockhart; Zeruesenay Desta

  Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro

  British Journal of Clinical Pharmacology. 2004;58(3):277-287.
  21

• 134.

  2004

  Sheldon H. Preskorn; David Flockhart

  2004 Guide to Psychiatric Drug Interactions

  Primary Psychiatry. 2004;11(2):39-60.
  11

• 135.

  2004

  Beth Rosenshein; David A. Flockhart; Herbert Ho

  Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote

  American Journal of the Medical Sciences. 2004;327(5):289-293.
  3

• 136.

  2004

  Deborah L Flores; Israel Alvarado; Ma-Li Wong; Julio Licinio; David Flockhart

  Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans.

  Annals of internal medicine. 2004;140(11):W71.
  4

• 137.

  2004

  Brooke Ratliff; Eric C. Dietze; Gregory R. Bean; Cassandra Moore; Sam Wanko; Victoria L. Seewaldt; Riccardo Ponzone; Nicoletta Biglia; Piero Sismondi; Ernst A. Lien; et al.

  Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine (multiple letters) [1]

  Journal of the National Cancer Institute. 2004;96(11):883-885.
  3

• 138.

  2004

  V. Stearns; N.E. Davidson; D.A. Flockhart

  Pharmacogenetics in the treatment of breast cancer

  Pharmacogenomics Journal. 2004;4(3):143-153.
  31

• 139.

  2004

  Kazuki Takada; Million Arefayene; Zeruesenay Desta; Cheryl H. Yarboro; Dimitrios T. Boumpas; James E. Balow; David A. Flockhart; Gabor G. Illei

  Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis

  Arthritis and Rheumatism. 2004;50(7):2202-2210.
  85

• 140.

  2004

  Michael D. Johnson; Hong Zuo; Kyung-Hoon Lee; Joseph P. Trebley; James Michael Rae; Ross V. Weatherman; Zeruesanay Desta; David A. Flockhart; Todd C. Skaar

  Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

  Breast Cancer Research and Treatment. 2004;85(2):151-159.
  189

• 141.

  2004

  Pascal Le Corre; Robert J. Parmer; Mala T. Kailasam; Brian P. Kennedy; Todd P. Skaar; Herbert Ho; Roger Leverge; Douglas W. Smith; Michael G. Ziegler; Paul A. Insel; et al.

  Human sympathetic activation by α ₂-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism

  Clinical Pharmacology and Therapeutics. 2004;76(2):139-153.
  22

• 142.

  2004

  Jacqueline Ramírez; Federico Innocenti; Erin G. Schuetz; David A. Flockhart; Mary V. Relling; Raymond Santucci; Mark J. Ratain

  CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes

  Drug Metabolism and Disposition. 2004;32(9):930-936.
  39

• 143.

  2004

  Zeruesenay Desta; Bryan A. Ward; Nadia V. Soukhova; David A. Flockhart

  Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6

  Journal of Pharmacology and Experimental Therapeutics. 2004;310(3):1062-1075.
  243

• 144.

  2003

  Russ B. Altman; David A. Flockhart; Stephen T. Sherry; Diane E. Oliver; Daniel L. Rubin; Teri E. Klein

  Indexing pharmacogenetic knowledge on the world wide web

  Pharmacogenetics. 2003;13(1):3-5.
  14

• 145.

  2003

  D.A. Flockhart; J.M. Rae

  Cytochrome P450 3A pharmacogenetics: The road that needs traveled

  Pharmacogenomics Journal. 2003;3(1):3-5.
  22

• 146.

  2003

  Curtis J. Rosebraugh; Yi Tsong; Feng Zhou; Min Chen; Ann Corken Mackey; Charlene Flowers; Denise Toyer; David A. Flockhart; Peter K. Honig

  Improving the quality of adverse drug reaction reporting by 4th-year medical students

  Pharmacoepidemiology and Drug Safety. 2003;12(2):97-101.
  8

• 147.

  2003

  Bryan A. Ward; J. Christopher Gorski; David R. Jones; Stephen D. Hall; David A. Flockhart; Zeruesenay Desta

  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

  Journal of Pharmacology and Experimental Therapeutics. 2003;306(1):287-300.
  247

• 148.

  2003

  M. Desai; J.E. Tanus-Santos; L. Li; J.C. Gorski; M. Arefayene; Y. Liu; Z. Desta; D.A. Flockhart

  Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6

  Pharmacogenomics Journal. 2003;3(2):105-113.
  15

• 149.

  2003

  Million Arefayene; Todd C. Skaar; Xiaojiong Zhao; James M. Rae; Jose E. Tanus-Santos; Ulrich Brinkmann; Ilka Brehm; Ulrike Salat; Anne Nguyen; Zeruesenay Desta; et al.

  Sequence diversity and functional characterization of the 5′-regulatory region of human CYP2C19

  Pharmacogenetics. 2003;13(4):199-206.
  9

• 150.

  2003

  Kyung-Hoon Lee; Bryan A. Ward; Zeruesenay Desta; David A. Flockhart; David R. Jones

  Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: Application to a clinical trial

  Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2003;791(1-2):245-253.
  50

• 151.

  2003

  Mehul Desai; Lang Li; Zeruesenay Desta; Marek Malik; David Flockhart

  Variability of heart rate correction methods for the QT interval

  British Journal of Clinical Pharmacology. 2003;55(6):511-517.
  41

• 152.

  2003

  James M. Rae; Kevin E. Cordero; Joshua O. Scheys; Marc E. Lippman; David A. Flockhart; Michael D. Johnson

  Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples

  Pharmacogenetics. 2003;13(8):501-507.
  39

• 153.

  2003

  Guangyuan Zeng; Zhiqiang Hu; Michael S. Kinch; Chong-Xian Pan; David A. Flockhart; Chinghai Kao; Thomas A. Gardner; Shaobo Zhang; Lang Li; Lee Ann Baldridge; et al.

  High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia

  American Journal of Pathology. 2003;163(6):2271-2276.
  64

• 154.

  2003

  Vered Stearns; Michael D. Johnson; James Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F. Hayes; Zeruesenay Desta; David A. Flockhart

  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

  Journal of the National Cancer Institute. 2003;95(23):1758-1764.
  439

• 155.

  2002

  D. Nikoloff; J.-C. Shim; M. Fairchild; N. Patten; B.A. Fijal; W.H. Koch; A. MacPherson; D. Flockhart; Y.-R. Yoon; J.-S. Yoon; et al.

  Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics

  Pharmacogenomics Journal. 2002;2(6):400-407.
  18

• 156.

  2002

  Jae-Gook Shin; Ji-Young Park; Min-Jung Kim; Ji-Hong Shon; Young-Ran Yoon; In-June Cha; Sang-Seop Lee; Se-Wook Oh; Sang-Woo Kim; David A. Flockhart

  Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: Mechanism of drug interaction between TCAs and phenytoin

  Drug Metabolism and Disposition. 2002;30(10):1102-1107.
  56

• 157.

  2002

  David A. Flockhart; Sally Usdin Yasuda; John C. Pezzullo; Björn C. Knollmann

  Teaching rational prescribing: A new clinical pharmacology curriculum for medical schools

  Naunyn-Schmiedeberg's Archives of Pharmacology. 2002;366(1):33-43.
  22

• 158.

  2002

  Jose E. Tanus-Santos; Mehul Desai; Leslie R. Deak; John C. Pezzullo; Darrell R. Abernethy; David A. Flockhart; Jane E. Freedman

  Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol

  Pharmacogenetics. 2002;12(5):407-413.
  66

• 159.

  2002

  David A. Flockhart; Harold S. Nelson

  Single isomer versus racemate: Is there a difference? Clinical comparisons in allergy and gastroenterology

  CNS Spectrums. 2002;7(4 SUPPL. 1):23-27.
  2

• 160.

  2002

  G. Marino; V.K. Rustgi; G. Salzberg; L.B. Johnson; P.C. Kuo; J.S. Plotkin; D.A. Flockhart

  Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease

  Alimentary Pharmacology and Therapeutics. 2002;16(2):235-242.
  6

• 161.

  2002

  Zeruesenay Desta; G.M. Wu; A.M. Morocho; D.A. Flockhart

  The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6

  Drug Metabolism and Disposition. 2002;30(3):336-343.
  58

• 162.

  2002

  Zeruesenay Desta; Nadia Soukhova; David A. Flockhart

  In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin

  Journal of Clinical Psychopharmacology. 2002;22(2):162-168.
  0

• 163.

  2002

  Ji-Hong Shon; Young-Ran Yoon; Kyoung-Ah Kim; Young-Chae Lim; Kwang-Jae Lee; Ji-Young Park; In-June Cha; David A. Flockhart; Jae-Gook Shin

  Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

  Pharmacogenetics. 2002;12(2):111-119.
  60

• 164.

  2002

  James M. Rae; Nadia V. Soukhova; David A. Flockhart; Zeruesenay Desta

  Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: Implications for cyclophosphamide metabolism

  Drug Metabolism and Disposition. 2002;30(5):525-530.
  74

• 165.

  2002

  Michael W. Jann; Troy L. ZumBrunnen; Yusuf R. Kazmi; Chad M. VanDenBerg; Hiral D. Desai; Donald J. Weidler; David A. Flockhart

  Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype

  Drug Metabolism and Drug Interactions. 2002;19(1):1-11.
  6

• 166.

  2002

  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A. Flockhart

  Clinical significance of the cytochrome P450 2C19 genetic polymorphism

  Clinical Pharmacokinetics. 2002;41(12):913-958.
  396

• 167.

  2002

  David A. Flockhart; Jose E. Tanus-Santos

  Implications of cytochrome P450 interactions when prescribing medication for hypertension

  Archives of Internal Medicine. 2002;162(4):405-412.
  61

• 168.

  2002

  Vincent J. Caracciolo; Benjamin M. Shaefer; Pamela Charney; David A. Flockhart; Jose Eduardo Dos Santos

  Ethnic, racial, and sex-specific factors are important in cardiovascular pharmacotherapeutics [5] (multiple letters)

  Archives of Internal Medicine. 2002;162(21):2494-2495.
  0

• 169.

  2001

  Zeruesenay Desta; Kari T. Kivistö; Jari J. Lilja; Janne T. Backman; Nadia Soukhova; Pertti J. Neuvonen; David A. Flockhart

  Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice

  British Journal of Clinical Pharmacology. 2001;52(4):399-407.
  12

• 170.

  2001

  C.J. Rosebraugh; D.A. Flockhart; S.U. Yasuda; R.L. Woosley

  Olanzapine-induced rhabdomyolysis

  Annals of Pharmacotherapy. 2001;35(9):1020-1023.
  22

• 171.

  2001

  Zeruesenay Desta; Nadia Soukhova; Alan M. Morocho; David A. Flockhart

  Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: Major role of CYP3A

  Journal of Pharmacology and Experimental Therapeutics. 2001;298(2):508-520.
  23

• 172.

  2001

  C.J. Rosebraugh; D.A. Flockhart; S.U. Yasuda; R.L. Woosley

  Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient

  Journal of Clinical Pharmacology. 2001;41(2):224-227.
  27

• 173.

  2001

  Jae-Gook Shin; Khadidjatou Kane; David A. Flockhart

  Potent inhibition of CYP2D6 by haloperidol metabolites: Stereoselective inhibition by reduced haloperidol

  British Journal of Clinical Pharmacology. 2001;51(1):45-52.
  27

• 174.

  2001

  Z. Desta; N.V. Soukhova; D.A. Flockhart

  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A

  Antimicrobial Agents and Chemotherapy. 2001;45(2):382-392.
  66

• 175.

  2001

  J.E. Tanus-Santos; M. Desai; D.A. Flockhart

  Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants

  Pharmacogenetics. 2001;11(8):719-725.
  174

• 176.

  2001

  James M. Rae; Michael D. Johnson; Marc E. Lippman; David A. Flockhart

  Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays

  Journal of Pharmacology and Experimental Therapeutics. 2001;299(3):849-857.
  153

• 177.

  2001

  C.J. Rosebraugh; P.K. Honig; S.U. Yasuda; J.C. Pezzullo; D.A. Flockhart; R.L. Woosley

  Formal education about medication errors in internal medicine clerkships [1]

  Journal of the American Medical Association. 2001;286(9):1019-1020.
  18

• 178.

  2001

  Z. Desta; K.T. Kivistö; J.J. Lilja; J.T. Backman; P.J. Neuvonen; N. Soukhova; D.A. Flockhart

  Effect of grapefruit juice (GFJ) on the stereo-selective pharmacokinetics (PK) of cisapride (CIS) and cardiac qtc interval in healthy volunteers

  Clinical Pharmacology and Therapeutics. 2001;69(2):P82.
  3

• 179.

  2001

  Z. Desta; J. Park; N. Soukhova; D.A. Flockhart

  Mechanism-based inactivation of CYP2C19 and CYP2D6 by tamoxifen (TAM) and its metabolite n-desmethyltamoxifen (NDTAM)

  Clinical Pharmacology and Therapeutics. 2001;69(2):P9.
  1

• 180.

  2001

  A.M. Morocho; Z. Desta; G.M. Wu; N.V. Soukova; J.M. Rae; D.A. Flockhart

  Characterization of tamoxifen metabolism to a novel, putative active metabolite

  Clinical Pharmacology and Therapeutics. 2001;69(2):P68.
  2

• 181.

  2001

  X. Zhao; J. Rae; D.A. Flockhart

  Cloning and sequencing of 5′-regulatory region of CYP2C19

  Clinical Pharmacology and Therapeutics. 2001;69(2):P72.
  1

• 182.

  2001

  C.J. Rosebraugh; P.K. Honig; A. Corken; C. Flowers; M. Mease; D. Toyer; M. Chen; D.A. Flockhart

  Improving the quality of adverse drug reaction reporting by 4th year medical students with a 15-minute intervention

  Clinical Pharmacology and Therapeutics. 2001;69(2):P93.
  1

• 183.

  2001

  C.J. Rosebraugh; S.U. Yasuda; J.C. Pezzullo; P.K. Honig; D.A. Flockhart; R.L. Woosley

  National survey of clinical pharmacology (CP) education in medical schools and internal medicine residency programs

  Clinical Pharmacology and Therapeutics. 2001;69(2):P93.
  0

• 184.

  2001

  J.M. Rae; M.D. Johnson; M.E. Lippman; D.A. Flockhart

  Microarray analysis of drug metabolizing enzyme induction in primary hepatocyte cultures

  Clinical Pharmacology and Therapeutics. 2001;69(2):P64.
  0

• 185.

  2001

  Z. Desta; N.V. Soukhova; D.A. Flockhart

  In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors (SSRIS) antidepressants and azithromycin

  Clinical Pharmacology and Therapeutics. 2001;69(2):P9.
  0

• 186.

  2001

  J.Y. Park; J.H. Shon; M.J. Kim; I.J. Cha; D.A. Flockhart; J.G. Shin

  In vitro inhibition of tricyclic antidepressants (TCAs) on phenytoin P-hydroxylation: Involvement of CYP2C9 and CYP2C19

  Clinical Pharmacology and Therapeutics. 2001;69(2):P78.
  0

• 187.

  2001

  D.A. Flockhart; D.F. Hayes; J.M. Rae; P. Bhargava; A. Morocho; V. Stearns

  Coprescription of paroxetine with tamoxifen to reduce hot flashes reduced plasma 4-hydroxy-N-desmethyl-tamoxifen plasma concentrations in a CYP2D6-dependent manner

  Clinical Pharmacology and Therapeutics. 2001;69(2):P10.
  0

• 188.

  2001

  D.A. Flockhart; N.V. Soukhova; Z. Desta

  Effect of selective serotonin reuptake inhibitors (SSRIS) and clonidine on the secondary metabolism of tamoxifen (TAM) by genetically polymorphic CYP2D6

  Clinical Pharmacology and Therapeutics. 2001;69(2):P10.
  0

• 189.

  2001

  Grace M. Wu; Zeruesenay Desta; Alan M. Morocho; David A. Flockhart

  The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6

  Clinical Pharmacology and Therapeutics. 2001;69(2):P71.
  0

• 190.

  2001

  Leslie R. Deak; Vicki Burack; Dave Flockhart; Jane E. Freedman

  The effect of tamoxifen and its metabolites on platelet function and nitric oxide release

  Clinical Pharmacology and Therapeutics. 2001;69(2):P32.
  0

• 191.

  2000

  Marion L. Williams; Pankaj Bhargava; Ilham Cherrouk; John L. Marshall; David A. Flockhart; Irving W. Wainer

  A discordance of the cytochrome P450 2C19 genotype and phenotype patients with advanced cancer

  British Journal of Clinical Pharmacology. 2000;49(5):485-488.
  38

• 192.

  2000

  David A. Flockhart; Zeruesenay Desta; Subena K. Mahal

  Selection of drugs to treat gastro-oesophageal reflux disease: The role of drug interactions

  Clinical Pharmacokinetics. 2000;39(4):295-309.
  39

• 193.

  2000

  Zeruesenay Desta; Nadia Soukhova; Subena K. Mahal; David A. Flockhart

  Interaction of cisapride with the human cytochrome P450 system: Metabolism and inhibition studies

  Drug Metabolism and Disposition. 2000;28(7):789-800.
  33

• 194.

  2000

  Said M. Baidas; Eric P. Winer; Gini F. Fleming; Lyndsay Harris; James M. Pluda; Jeanette G. Crawford; Hideko Yamauchi; Claudine Isaacs; John Hanfelt; Mariella Tefft; et al.

  Phase II evaluation of thalidomide in patients with metastatic breast cancer

  Journal of Clinical Oncology. 2000;18(14):2710-2717.
  94

• 195.

  2000

  Robert E. Benton; Mark Sale; David A. Flockhart; Raymond L. Woosley

  Greater quinidine-induced QTc interval prolongation in women

  Clinical Pharmacology and Therapeutics. 2000;67(4):413-418.
  78

• 196.

  2000

  D.A. Flockhart; J.R. Oesterheld

  Cytochrome P450-mediated drug interactions

  Child and Adolescent Psychiatric Clinics of North America. 2000;9(1):43-76.
  32

• 197.

  2000

  David A. Flockhart; Milou-Daniel Drici; Thomas Kerbusch; Nadia Soukhova; Emily Richard; Philip L. Pearle; Subena K. Mahal; Victoria J. Babb

  Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome

  Journal of Clinical Psychopharmacology. 2000;20(3):317-324.
  55

• 198.

  2000

  Young-Ran Yoon; In-June Cha; Ji-Hong Shon; Kyung-Ah Kim; Young-Nam Cha; In-Jin Jang; Chan-Woong Park; Sang-Goo Shin; David A. Flockhart; Jae-Gook Shin

  Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects

  Clinical Pharmacology and Therapeutics. 2000;67(5):567-576.
  39

• 199.

  2000

  R. Abbas; C.P. Chow; N.J. Browder; D. Thacker; S.L. Bramer; C.J. Fu; W. Forbes; M. Odomi; D.A. Flockhart

  In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms

  Human and Experimental Toxicology. 2000;19(3):178-184.
  30

• 200.

  2000

  Jae Wook Ko; Zeruesenay Desta; Nadia V. Soukhova; Timothy Tracy; David A. Flockhart

  In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6

  British Journal of Clinical Pharmacology. 2000;49(4):343-351.
  78

• 201.

  2000

  Darrell R. Abernethy; David A. Flockhart

  Molecular basis of cardiovascular drug metabolism: Implications for predicting clinically important drug interactions

  Circulation. 2000;101(14):1749-1753.
  34

• 202.

  2000

  Zeruesenay Desta; Nadia V. Soukhova; Alan Morocho; Jae Park; Subena K. Mahal; David A. Flockhart

  Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: Application to pharmacokinetic study

  Journal of Chromatography B: Biomedical Sciences and Applications. 2000;744(2):263-272.
  13

• 203.

  1999

  Hong-Guang Xie; C. Michael Stein; Richard B. Kim; Grant R. Wilkinson; David A. Flockhart; Alastair J.J. Wood

  Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world

  Pharmacogenetics. 1999;9(5):539-549.
  130

• 204.

  1999

  Jae-Gook Shin; Nadia Soukhova; David A. Flockhart

  Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6

  Drug Metabolism and Disposition. 1999;27(9):1078-1084.
  105

• 205.

  1999

  Z. Desta; D.A. Flockhart

  A fatality involving moclobemide, sertraline and pimozide [2]

  Journal of Forensic Sciences. 1999;44(1):231-232.
  2

• 206.

  1999

  Zeruesenay Desta; Thomas Kerbusch; David A. Flockhart

  Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)

  Clinical Pharmacology and Therapeutics. 1999;65(1):10-20.
  76

• 207.

  1999

  Jae-Wook Ko; In-Jin Jang; Jae-Gook Shin; Sang-Keon Nam; Sang-Goo Shin; David A. Flockhart

  Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers

  Clinical Pharmacology and Therapeutics. 1999;65(6):606-614.
  17

• 208.

  1999

  R. Yuan; D.A. Flockhart; J.D. Balian

  Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam

  Journal of Clinical Pharmacology. 1999;39(11):1109-1125.
  51

• 209.

  1999

  D.L. Thacker; I. Wainer; C. Lerch; K. Fried; D.A. Flockhart

  Metabolism of an anabolic androgenic steroid, oxymetholone by human cytochrome P450s

  Clinical Pharmacology and Therapeutics. 1999;65(2):136.
  1

• 210.

  1999

  Zeruesenay Desta; David Thacker; Nadia Soukhova; Jae-Gook Shin; David A. Flockhart

  Identification and characterization of human cytchrome P450 (CYP) isoforms interacting with cisapride

  Clinical Pharmacology and Therapeutics. 1999;65(2):126.
  3

• 211.

  1999

  Stephen Donahue; David A. Flockhart; Darrell R. Abernethy

  Ticlopidine inhibits phenytoin clearance

  Clinical Pharmacology and Therapeutics. 1999;66(6):563-568.
  15

• 212.

  1999

  M.L. Williams; P. Bhargava; J.L. Marshall; D.A. Flockhart; I.W. Wainer

  Reduced CYP2C19 activity in cancer patients

  Clinical Pharmacology and Therapeutics. 1999;65(2):196.
  0

• 213.

  1999

  J.G. Shin; K. Kane; D.A. Flockhart

  Haloperidol metabolites inhibit CYP2D6 catalyzed dextromethorphan O-demethylation in vitro

  Clinical Pharmacology and Therapeutics. 1999;65(2):143.
  0

• 214.

  1998

  D.A. Flockhart; D.J. Webb

  Clinical pharmacology. Blue-chip technology.

  Lancet. 1998;352 Suppl 4:SIV2.
  0

• 215.

  1998

  David A. Flockhart; David J. Webb

  Blue-chip technology

  Lancet. 1998;352(SUPPL.4):SIV2.
  4

• 216.

  1998

  Milou-Daniel Drici; Wen X. Wang; Xioa-Ke Liu; Raymond L. Woosley; David A. Flockhart

  Prolongation of QT interval in isolated feline hearts by antipsychotic drugs

  Journal of Clinical Psychopharmacology. 1998;18(6):477-481.
  119

• 217.

  1998

  Zeruesenay Desta; Thomas Kerbusch; Nadia Soukhova; Emily Richard; Jae-Wook Ko; David A. Flockhart

  Identification and characterization of human cytochrome P450 isoforms interacting with pimozide

  Journal of Pharmacology and Experimental Therapeutics. 1998;285(2):428-437.
  52

• 218.

  1998

  Jae-Wook Ko; Zeruesenay Desta; David A. Flockhart

  Human N-demethylation of (S)-mephenytoin by cytochrome P450S 2C9 and 2B6

  Drug Metabolism and Disposition. 1998;26(8):775-778.
  50

• 219.

  1998

  Christoph Wandel; Chim C. Lang; Doug C. Cowart; Armand F. Girard; Steve Bramer; David A. Flockhart; Alastair J. J. Wood

  Effect of CYP3A inhibition on vesnarinone metabolism in humans

  Clinical Pharmacology and Therapeutics. 1998;63(5):506-511.
  8

• 220.

  1998

  Carol Braun Trapnell; Stephen R. Donahue; Jerry M. Collins; David A. Flockhart; David Thacker; Darrell R. Abernethy

  Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone

  Clinical Pharmacology and Therapeutics. 1998;64(6):597-602.
  19

• 221.

  1998

  David L. Thacker; Darrell R. Abernethy; Arthur Raines; David A. Flockhart

  Method for the determination of 5,5-diphenylbarbituric acid and its separation from 1,3-dimethoxymethyl-5,5-diphenylbarbituric acid in plasma by high-performance liquid chromatography

  Journal of Chromatography B: Biomedical Applications. 1998;710(1-2):149-155.
  1

• 222.

  1997

  S.R. Donahue; J.M. Collins; D.A. Flockhart; D.R. Abernethy; C.B. Trapnell

  Thalidomide pharmacokinetics do not change with chronic administration

  Clinical Pharmacology and Therapeutics. 1997;61(2):236.
  2

• 223.

  1997

  Jae-Wook Ko; Nadia Sukhova; David Thacker; Patricia Chen; David A. Flockhart

  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms

  Drug Metabolism and Disposition. 1997;25(7):853-862.
  163

• 224.

  1997

  Thomas Kerbusch; Zeruesenay Desta; Nadia V. Soukhova; David Thacker; David A. Flockhart

  Sensitive assay for pimozide in human plasma using high-performance liquid chromatography with fluorescence detection: Application to pharmacokinetic studies

  Journal of Chromatography B: Biomedical Applications. 1997;694(1):163-168.
  8

• 225.

  1997

  Stephen K. Donahue; David A. Flockhart; Darrell R. Abernethy; Jae-Wook Ko

  Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19

  Clinical Pharmacology and Therapeutics. 1997;62(5):572-577.
  53

• 226.

  1997

  David R. Moller; Maria Wysocka; Brian M. Greenlee; Xiaojing Ma; Larry Wahl; David A. Flockhart; Giorgio Trinchieri; Christopher L. Karp

  Inhibition of IL-12 Production by Thalidomide

  Journal of Immunology. 1997;159(10):5157-5161.
  179

• 227.

  1997

  D.A. Flockhart; E. Richard; N. Soukova; T. Kerbuscb

  Metabolism of pimozide by CYF3A and CYP2D6 in human liver microsomes

  Clinical Pharmacology and Therapeutics. 1997;61(2):232.
  0

• 228.

  1997

  J.-W. Ko; A.S. Macpherson; I.-J. Jang; S.-G. Shin; D.A. Flockhart

  The incidence of genetic polymorphisms of CYP 2C in a Korean population

  Clinical Pharmacology and Therapeutics. 1997;61(2):226.
  0

• 229.

  1997

  J.-W. Ko; N. Sukhova; D. Thacker; P. Chen; D.A. Flockhart

  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms

  Clinical Pharmacology and Therapeutics. 1997;61(2):171.
  0

• 230.

  1997

  W.X. Wang; D. Flockhart; M.-D. Drici; R.L. Woosley

  Synergistic effects of ketoconazole and pimozide on QT interval in isolated rabbit hearts: Influence of gender and pacing rate

  Clinical Pharmacology and Therapeutics. 1997;61(2):202.
  0

• 231.

  1996

  Jacqueline S. Marinac; John D. Balian; John W. Foxworth; Sandra K. Willsie; Jennifer C. Daus; Renius Owen; David A. Flockhart

  Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype

  Clinical Pharmacology and Therapeutics. 1996;60(2):138-144.
  45

• 232.

  1996

  Curtis Larson; Nicholas J. Cavuto; David A. Flockhart; Richard B. Weinberg

  Bioavailability and efficacy of omeprazole given orally and by nasogastric tube

  Digestive Diseases and Sciences. 1996;41(3):475-479.
  33

• 233.

  1996

  D.A. Flockhart

  Drug interactions, cardiac toxicity, and terfenadine: From bench to clinic?

  Journal of Clinical Psychopharmacology. 1996;16(2):101-103.
  25

• 234.

  1995

  Hakam F. Hadidi; Yacoub M. Irshaid; Raymond L. Woosley; Jeffrey R. Idle; David A. Flockhart

  S-Mephenytoin hydroxylation phenotypes in a Jordanian population

  Clinical Pharmacology and Therapeutics. 1995;58(5):542-547.
  11

• 235.

  1995

  John D. Balian; Nadia Sukhova; James W. Harris; Jan Hewett; Linda Pickle; Joyce A. Goldstein; Raymond L. Woosley; David A. Flockhart

  The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study

  Clinical Pharmacology and Therapeutics. 1995;57(6):662-669.
  137

• 236.

  1995

  D.A. Flockhart

  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19

  Clinical Pharmacokinetics. 1995;29(4 SUPPL. 1):45-52.
  66

• 237.

  1995

  T.A. Ketter; D.A. Flockhart; R.M. Post; K. Denicoff; P.J. Pazzaglia; L.B. Marangell; M.S. George; A.M. Callahan

  The emerging role of cytochrome P450 3A in psychopharmacology

  Journal of Clinical Psychopharmacology. 1995;15(6):387-398.
  150

• 238.

  1995

  D.J. Clauw; J. Hewett; C.A. Blank; P. Katz; D.A. Flockhart

  P450 metabolism in fibromyalgia

  Journal of Musculoskeletal Pain. 1995;3(4):25-32.
  0

• 239.

  1994

  David A. Flockhart; Daniel J. Clauw; Elaine Buchert Sale; Jan Hewett; Raymond L. Woosley

  Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome

  Clinical Pharmacology and Therapeutics. 1994;56(4):398-405.
  21

• 240.

  1994

  R.L. Woosley; D.A. Flockhart; W.A. Ray; M.R. Griffin; J. Avorn

  Evaluating drugs after their approval for clinical use [8]

  New England Journal of Medicine. 1994;330(19):1394-1395.
  1

• 241.

  1994

  D.J. Clauw; D.A. Flockhart; W. Mullins; P. Katz; T.A. Medsger Jr.

  Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements

  Journal of Rheumatology. 1994;21(12):2385-2387.
  4

• 242.

  1991

  E.R. Mohler; B. Monahan; M.D. Canty; D.A. Flockhart

  Cerebral abscess associated with dental procedure in hereditary haemorrhagic telangiectasia [6]

  Lancet. 1991;338(8765):508-509.
  10

• 243.

  1988

  M.R. Gordon; D. Flockhart; J.K. Zawadzki; T. Taylor; J.N. Ramey; R.C. Eastman

  Hypoglycemia due to inadvertent dispensing of chlorpropamide

  American Journal of Medicine. 1988;85(2):271-272.
  11

• 244.

  1988

  Michele R. Gordon; David Flockhart; Joanna K. Zawadzki; Terry Taylor; James N. Ramey; Richard C. Eastman

  Hypoglycemia due to inadvertent dispensing of chlorpropamide

  The American Journal of Medicine. 1988;85(2):270-271.
  2

• 245.

  1984

  D.A. Flockhart; W. Freist; J. Hoppe; T.M. Lincoln; J.D. Corbin

  ATP analog specificity of cAMP-dependent protein kinase, cGMP-dependent protein kinase, and phosphorylase kinase

  European Journal of Biochemistry. 1984;140(2):289-295.
  19

• 246.

  1984

  E.O. Nightingale; E. Stover; D.A. Flockhart; C. Goering

  Support urged for Syrian doctors.

  New England Journal of Medicine. 1984;310(12):803-804.
  0

• 247.

  1983

  D.A. Flockhart

  Removal of phosphate from proteins by the reverse reaction

  Methods in Enzymology. 1983;Vol. 99:14-20.
  1

• 248.

  1982

  D.A. Flockhart; J.D. Corbin

  Regulatory mechanisms in the control of protein kinases.

  CRC critical reviews in biochemistry. 1982;12(2):133-186.
  31

• 249.

  1982

  J.D. Corbin; S.R. Rannels; D.A. Flockhart; A.M. Robinson-Steiner; M.C. Tigani; S.O. Døskeland; R.H. Suva; R. Suva; J.P. Miller

  Effect of cyclic nucleotide analogs on intrachain site I of protein kinase isozymes.

  European Journal of Biochemistry. 1982;125(2):259-266.
  4

• 250.

  1980

  M.R. El-Maghrabi; W.S. Haston; D.A. Flockhart; T.H. Claus; S.J. Pilkis

  Studies on the phosphorylation and dephosphorylation of L-type pyruvate kinase by the catalytic subunit of cyclic AMP-dependent protein kinase

  Journal of Biological Chemistry. 1980;255(2):668-675.
  14

• 251.

  1980

  D.A. Flockhart; D.M. Watterson; J.D. Corbin

  Studies on functional domains of the regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase.

  Journal of Biological Chemistry. 1980;255(10):4435-4440.
  8

• 252.

  1979

  D.A. Flockhart; K. Siddle

  Lack of effect of insulin on guanosine 3':5'-cyclic monophosphate content of insulin-sensitive rat hepatocytes

  Biochemical Society Transactions. 1979;7(5):1033-1035.
  0

• 253.

  1979

  Sara A. Westwood; J.Paul Luzio; David A. Flockhart; Kenneth Siddle

  Investigation of the subcellular distribution of cyclic-AMP phosphodiesterase in rat hepatocytes, using a rapid immunological procedure for the isolation of plasma membrane

  BBA - General Subjects. 1979;583(4):454-466.
  0

• 254.

  1978

  S.A. Westwood; J.P. Luzio; D.A. Flockhart; K. Siddle

  Immunological isolation of hepatocyte plasma membranes

  Biochemical Society Transactions. 1978;6(1):278-280.
  0

• 255.

  1978

  J.D. Corbin; P.H. Sugden; L. West; D.A. Flockhart; T.M. Lincoln; D. McCarthy

  Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase

  Journal of Biological Chemistry. 1978;253(11):3997-4003.
  50

• 256.

  1978

  T.M. Lincoln; D.A. Flockhart; J.D. Corbin

  Studies on the structure and mechanism of activation of the guanosine 3':5'-monophosphate-dependent protein kinase

  Journal of Biological Chemistry. 1978;253(17):6002-6009.
  11

• 257.

  1977

  J.P. Riou; T.H. Claus; D.A. Flockhart; J.D. Corbin; S.J. Pilkis

  In vivo and in vitro phosphorylation of rat liver fructose-1,6-bisphosphatase

  Proceedings of the National Academy of Sciences of the United States of America. 1977;74(10):4615-4619.
  13